

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Heidi Ray Examiner #: 75244 Date: 4/10/03
Art Unit: 1625 Phone Number 30 1051153 Serial Number: 10048229
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

3701-4A16

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: See Prioris Copy

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Compounds + Proteins

BEST AVAILABLE COPY

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>Skaggs</u>	NA Sequence (#) _____	STN _____
Searcher Phone #: <u>308-4499</u>	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: <u>4/17/03</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: _____	Other _____	Other (specify) _____

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 16:31:30 ON 17 APR 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Apr 2003 VOL 138 ISS 16
 FILE LAST UPDATED: 16 Apr 2003 (20030416/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
 =>

=> d ibib abs hitrn 19 1-20

L9 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:463998 HCAPLUS

DOCUMENT NUMBER: 137:33135

TITLE: Process for the preparation of 2,7-dialkyl-5-amino-8-aryl-4-hydroxyoctanamides via reaction of pseudoephedrine-protected isopropylvalerolactone nitrones with Grignard reagents.

INVENTOR(S): Bellus, Daniel; Dondoni, Alessandro

PATENT ASSIGNEE(S): Speedel Pharma A.-G., Switz.

SOURCE: Eur. Pat. Appl., 18 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1215201	A2	20020619	EP 2001-128462	20011206
EP 1215201	A3	20030129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002082302	A1	20020627	US 2001-14400	20011214
PRIORITY APPLN. INFO.:		CH 2000-2442	A	20001214
OTHER SOURCE(S):		CASREACT 137:33135; MARPAT 137:33135		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. (I; R1, R2 = H, alkyl, haloalkyl, alkoxy, alkoxyalkyl, alkoxyalkoxy; R3, R4 = alkyl; R5 = alkyl, hydroxyalkyl, alkoxyalkyl,

alkanoyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkanoylamidoalkyl, etc.), were prepd. by treatment of aldehydes (II; R4 as above) with ZNHOH (Z = protecting group) then with a organometallic deriv. of (III; R1-R3 as above; Y = Cl, Br; iodo) followed by deprotection and amidation steps. Thus, title compd. (IV) was prepd. from alc. (V) and aralkyl chloride (VI) in several steps.

IT 173334-57-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP. (Preparation)

(process for the prepn. of 2,7-dialkyl-5-amino-8-aryl-4-hydroxyoctanamides via reaction of pseudoephedrine-protected isopropylvalerolactone nitrones with Grignard reagents)

L9 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:428761 HCAPLUS

DOCUMENT NUMBER: 137:11000

TITLE: Pharmaceutical compositions containing angiotensin receptor blockers for treating sexual dysfunction

INVENTOR(S): Sahota, Pritam Singh

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.

SOURCE: PCT Int. Appl., 26 pp.

DOCUMENT TYPE: CODEN: PIXXD2

LANGUAGE: Patent

FAMILY ACC. NUM. COUNT: 1 English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043807	A2	20020606	WO 2001-EP13976	20011129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2002026365	A5	20020611	AU 2002-26365	20011129
US 2002107236	A1	20020808	US 2001-8445	20011203
PRIORITY APPLN. INFO.: US 2000-250540P P 20001201				
WO 2001-EP13976 W 20011129				

AB The present invention relates to methods of treating sexual dysfunction assocd. with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor. A film-coated tablet contained valsartan 8.00, microcryst. cellulose 54.00, crospovidone 20.00, colloidal silica 1.50, magnesium stearate 4.5, and Diolack pale red 00F34899 7.00 mg.

IT 173334-57-1, Aliskiren

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. contg. angiotensin receptor blockers for treating sexual dysfunction)

L9 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:391521 HCAPLUS

DOCUMENT NUMBER: 136:391012


TITLE: Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

INVENTOR(S): Hewitt, William; Vasella, Daniel Lucius; Webb, Randy Lee

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen
Verwaltungsgesellschaft M.B.H.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040007	A1	20020523	WO 2001-EP13241	20011115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2002023680	A5	20020527	AU 2002-23680	20011115
PRIORITY APPLN. INFO.:			GB 2000-28151	A 20001117
			WO 2001-EP13241	W 20011115

GI



AB The invention relates to a combination comprising the renin inhibitor (I) or a pharmaceutically acceptable salt thereof. Formulations were given contg. the AT1 receptor antagonist valsartan.

IT 173334-57-1

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic combinations comprising a renin inhibitor for cardiovascular diseases)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:357902 HCAPLUS

DOCUMENT NUMBER: 137:93585

TITLE: The Power of Visual Imagery in Synthesis Planning.
Stereocontrolled Approaches to CGP-60536B, a Potent Renin Inhibitor

AUTHOR(S): Hanessian, Stephen; Claridge, Stephen; Johnstone, Shawn

CORPORATE SOURCE: Department of Chemistry, Universite de Montreal,
 Montreal, QC, H3C 3J7, Can.
 SOURCE: Journal of Organic Chemistry (2002), 67(12), 4261-4274
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:93585
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Nonracemic arylhydroxyaminooctanoic acids I (R = H, MeO; R1 = Me2CH, Bu), generic motifs of a new class of potent nonpeptide renin inhibitors with potential as antihypertensive agents, are prep'd. stereoselectively by two different synthetic routes. In order to incorporate one of the key iso-Pr groups in I, the enolate of Me L-pyroglutamate is added to acetone to give a tertiary alc.; the tertiary alc. is left in place during the subsequent amide redn. and acid-mediated addn. of methanol to the hemiaminal to give an aminal to direct the addn. of aryllithium or arylmagnesium cuprates to the aminal to give arylpyrrolidinecarboxylates stereoselectively which undergo elimination of the tertiary alc. moiety and hydrogenation to give the key intermediates II (R2 = H, MeO). One of the routes uses a Dieckmann condensation of an N-succinoyl pyrrolidinecarboxylate to generate an indolizine III which undergoes stereoselective redn. followed by amide redn., selective oxidn. and cyclization to generate an pyrrolidinylfuranone IV (R3 = R4 = H); enolate formation, addn. of acetone, elimination of the tertiary alc., and hydrogenation provides IV (R3 = H; R4 = Me2CH) which is amidated to provide I (R = H; R1 = Me2CH). The stereoselectivity of this route is mediated through the use of a cyclic template inspired by a visual reorientation of the structure of I. A second route from II (R2 = MeO) relies on the addn. of a carbon chain to the ester moiety of II followed by stereoselective redn., oxidn. and cyclization to give the intermediate IV (R3 = MeO; R4 = H) which is processed as with the Ph analog except using butylamine in the ultimate amidation to give I (R = MeO; R1 = Bu). Addn. of di-Me methylphosphonate to II (R2 = MeO) followed by condensation of the phosphonate with Me glyoxalate mediated by diisopropylethylamine and lithium chloride, redn. of the double bond and the carbonyl groups, and selective oxidn. and cyclization gives IV (R3 = MeO; R4 = H); formation of a furanone enolate and addn. of acetone, elimination of the tertiary alc., hydrogenation, and trimethylaluminum-mediated amidation with butylamine yields I (R = MeO; R1 = Bu). Crystal structures of intermediates are given (no data).

IT 173334-57-1P, CGP60536B

RL: PNU (Preparation, unclassified); PREP (Preparation).

(asym. prepn. of substituted aryloctanoic acid renin inhibitors from Me L-pyroglutamate using either a cyclic template or acyclic appendages to control the stereochem.)

REFERENCE COUNT: 109. THERE ARE 109 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:231708 HCAPLUS

DOCUMENT NUMBER: 137:217185

TITLE: Aliskiren fumarate

AUTHOR(S): Mealy, N. E.; Castaner, J.; Castaner, R. M.; Silvestre, J.

CORPORATE SOURCE: Prous Science, Barcelona, 08080, Spain

SOURCE: Drugs of the Future (2001), 26(12), 1139-1148

CODEN: DRFUD4; ISSN: 0377-8282

PUBLISHER: Prous Science
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. The synthesis of aliskiren fumarate is shown in seven schemes. Clin. studies, pharmacokinetics, and pharmacol. actions of aliskiren fumarate are also discussed.

IT 173334-58-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of aliskiren fumarate)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:98876 HCAPLUS

DOCUMENT NUMBER: 136:350363

TITLE: Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril

AUTHOR(S): Nussberger, Juerg; Wuerzner, Gregoire; Jensen, Chris; Brunner, Hans R.

CORPORATE SOURCE: Division of Hypertension and Vascular Medicine, Univ. Hospital Lausanne, Basel, Switz.

SOURCE: Hypertension (2002), 39(1), e1-e8

CODEN: HPRTDN; ISSN: 0194-911X

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Renin is the main determinant of angiotensin (Ang) II levels. It, therefore, always appeared desirable to reduce Ang II levels by direct inhibition of renin. So far, specific renin inhibitors lacked potency and/or oral availability. The authors tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concn. [IC50] in the low nanomolar range) in 18 healthy volunteers on a const. 100 mmol/d Na diet using a double-blind, 3-way crossover protocol. In 3 periods of 8 days, sep'd. by wash-outs of 6 days, each volunteer received 2 dosage levels of Aliskiren (low before high; 40 and 80 or 160 and 640 mg/d) and randomized placebo or 20 mg enalapril. Aliskiren was well tolerated. Not surprisingly, blood pressure and heart rate remained unchanged in these normotensive subjects. There was a dose-dependent decrease in plasma renin activity, Ang I, and Ang II following single doses of Aliskiren starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89 and 75% on Days 1 and 8, resp., when the highest dose of Aliskiren was compared with placebo. At the same time, mean plasma active renin was increased 16- and 34-fold at the highest dose of Aliskiren. Plasma drug levels of Aliskiren were dose-dependent with maximal concns. reached between 3 to 6 h after administration; steady state was reached between 5 and 8 days after multiple dosing. Less than 1% of dose was excreted in the urine. Plasma and urinary aldosterone levels were decreased after doses of Aliskiren \geq 80 mg and after enalapril. Aliskiren at 160 and 640 mg enhanced natriuresis on Day 1 by +45 and +62%, resp., compared with placebo (100%, ie, 87 mmol/24h) and enalapril (+54%); kaliuresis remained unchanged. In conclusion, the renin inhibitor Aliskiren dose-dependently decreases Ang II levels in humans following oral administration. The effect is long-lasting and, at a dose of 160 mg, is equiv. to that of 20 mg enalapril. Aliskiren has the potential to become the 1st orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.

IT 173334-57-1, Aliskiren

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral renin inhibitor aliskiren)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:89992 HCAPLUS

DOCUMENT NUMBER: 136:134582

TITLE: Process for the preparation of substituted octanoyl amides

INVENTOR(S): Herold, Peter; Stutz, Stefan

PATENT ASSIGNEE(S): Speedel Pharma A.-G., Switz.

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008172	A1	20020131	WO 2001-CH400	20010626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: CH 2000-1464 A 20000725

OTHER SOURCE(S): CASREACT 136:134582; MARPAT 136:134582

GI



AB A process for the prepn. of octanoyl amides, such as I [R1, R2 = H, alkyl, haloalkyl, alkoxy, alkyloxyalkyl, etc.; R3, R4 = alkyl; R5 = alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, acylalkyl, etc.], was described. Thus, amino-amide I [R1 = O(CH2)3OMe, R2 = OMe, R3 = R4 = CHMe2, R5 = CH2CMe2CONH2] was prepd. via reaction of azide II with H2NCH2CMe2CONH2 using 2-hydroxypyridine and Et3N and stirring for 16 h to achieve opening of the lactone and concomitant formation of the corresponding azido-amide in quant. yield. The azido-amide was subsequently hydrogenated for 3 h using Pd/C and H2N(CH2)2OH in Me3COMe at 3.0 bar to give the desired amino-amide in 81% yield.

IT 173334-57-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP

(Preparation)

(process for the prepn. of substituted octanoyl amides)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:31398 HCAPLUS

DOCUMENT NUMBER: 136:85612

TITLE: Process for the prepn. of substituted octanoyl amides utilizing a stereoselective halolactonization

INVENTOR(S): Herold, Peter; Stutz, Stefan; Spindler, Felix

PATENT ASSIGNEE(S): Speedel Pharma Ag, Switz.

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002508	A1	20020110	WO 2001-CH399	20010626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1296935	A1	20030402	EP 2001-940047	20010626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:		CH 2000-1329 A 20000705		
		CH 2000-2450 A 20001215		
		WO 2001-CH399 W 20010626		

OTHER SOURCE(S): CASREACT 136:85612; MARPAT 136:85612


GI




I



II



III



IV

AB A process for the prepn. of compds. I [R = 3-R1-4-R2-C6H3CH2; R1-2 = H, alkyl, haloalkyl, alkoxy, alkoxy-alkyl, etc.] is disclosed. The process involves NBS induced lactonization of II to the cis-lactone III [CH2Cl2,

(prepn. of .beta.-amino acid-contg. dipeptide isostere as renin inhibitor using a nitron intermediate)

IT 325154-32-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of .beta.-amino acid-contg. dipeptide isostere as renin inhibitor using a nitron intermediate)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:101097 HCAPLUS

DOCUMENT NUMBER: 134:162829

TITLE: Preparation of 5-amino-8-aryl-2,7-dialkyl-4-hydroxyoctanoamides

INVENTOR(S): Herold, Peter; Stutz, Stefan; Indolese, Adriano

PATENT ASSIGNEE(S): Speedel Pharma Ag, Switz.

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009083	A1	20010208	WO 2000-CH384	20000713
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1200390	A1	20020502	EP 2000-940108	20000713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:				
			CH 1999-1401	A 19990729
			CH 2000-44	A 20000111
			WO 2000-CH384	W 20000713

OTHER SOURCE(S): CASREACT 134:162829; MARPAT 134:162829

AB R1CH2CHR3CH2CHR6CHR7CHR4COR [I; R = NHR5, R1 = 3,4-(un)substituted Ph, R6 = NH2, R7 = OH][II; R3,R4 = alkyl, R5 = (un)substituted alkyl] were prepd. by (stereoselective) halohydroxylation and cyclization of (chiral) (E)-I (R = NR2R8; R2,R8 = alkyl, R2R8 = atoms to complete a ring, R6R7 = bond)(III) (prepn. given) to give (chiral) I (RR7 = O, R6 = halo) followed by azidation, ring-opening amidation by R5NH2, and redn. All-(S)-II can be obtained with a high degree of purity from (2S,7R)-III.

IT 325154-33-4P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of 5-amino-8-aryl-2,7-dialkyl-4-hydroxyoctanoamides)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:872595 HCAPLUS

DOCUMENT NUMBER: 134:162794

TITLE: A convergent synthesis of the renin inhibitor CGP60536B

AUTHOR(S): Sandham, D. A.; Taylor, R. J.; Carey, J. S.; Fassler,

CORPORATE SOURCE: A. Novartis Pharmaceuticals UK Ltd, Horsham Research Centre, Horsham, West Sussex, RH12 5AB, UK
 SOURCE: Tetrahedron Letters (2000), 41(51), 10091-10094
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:162794
 AB Pseudoephedrine serves as a dual purpose chiral auxiliary and protecting group in the synthesis of the novel orally active renin inhibitor CGP60536B, a peptidomimetic.
 IT 173334-58-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (asym. synthesis of peptidomimetic CGP60536B)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:872594 HCAPLUS

DOCUMENT NUMBER: 134:162793

TITLE: A convergent synthesis approach towards CGP60536B, a

non-peptide orally potent renin inhibitor, via an enantiomerically pure keto lactone intermediate

Rueger, H.; Stutz, S.; Goschke, R.; Spindler, F.; Maibaum, J.

AUTHOR(S):

CORPORATE SOURCE: Metabolic and Cardiovascular Diseases, Novartis Pharma AG, Basel, CH-4002, Switz.

SOURCE: Tetrahedron Letters (2000), 41(51), 10085-10089

CODEN: TELEAY; ISSN: 0040-4039



PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:162793

GI



AB A convergent synthesis of the potent orally active non-peptide renin inhibitor CGP60536B I is reported. The key reaction employs the coupling of the enantiopure Grignard species derived from chloride II with the diastereomerically pure gamma-lactone III. The stereoselective redn. of

the resulting ketone was thoroughly investigated.

IT 173334-58-2P 325154-32-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis of CGP60536B peptidomimetic via enantiopure keto
lactone intermediate)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:536434 HCAPLUS

DOCUMENT NUMBER: 133:217282

TITLE: Structure-based drug design: the discovery of novel
nonpeptide orally active inhibitors of human renin
AUTHOR(S): Rahuel, J.; Rasetti, V.; Maibaum, J.; Rueger, H.;
Goschke, R.; Cohen, N-C.; Stutz, S.; Cumin, F.;
Fuhrer, W.; Wood, J. M.; Grutter, M. G.

CORPORATE SOURCE: Metabolic and Cardiovascular Diseases, Novartis Pharma
AG, Basel, CH-4002, Switz.

SOURCE: Chemistry & Biology (2000), 7(7), 493-504

CODEN: CBOLE2; ISSN: 1074-5521

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Background: The aspartic proteinase renin plays an important physiol. role
in the regulation of blood pressure. It catalyzes the first step in the
conversion of angiotensinogen to the hormone angiotensin II. In the past,
potent peptide inhibitors of renin have been developed, but none of these
compds. has made it to the end of clin. trials. Our primary aim was to
develop novel nonpeptide inhibitors. Based on the available structural
information concerning renin-substrate interactions, we synthesized
inhibitors in which the peptide portion was replaced by lipophilic
moieties that interact with the large hydrophobic S1/S3-binding pocket in
renin. Results: Crystal structure anal. of renin-inhibitor complexes
combined with computational methods were employed in the medicinal-chem.
optimization process. Structure anal. revealed that the newly designed
inhibitors bind as predicted to the S1/S3 pocket. In addn., however,
these compds. interact with a hitherto unrecognized large, distinct,
sub-pocket of the enzyme that extends from the S3-binding site towards the
hydrophobic core of the enzyme. Binding to the S3sp sub-pocket was
essential for high binding affinity. This unprecedented binding mode
guided the drug-design process in which the mostly hydrophobic
interactions within subsite S3sp were optimized. Conclusions: Our design
approach led to compds. with high in vitro affinity and specificity for
renin, favorable bioavailability and excellent oral efficacy in lowering
blood pressure in primates. These renin inhibitors are therefore
potential therapeutic agents for the treatment of hypertension and related
cardiovascular diseases.

IT 173334-57-1 173399-55-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(nonpeptide orally active inhibitors of human renin)

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:310032 HCAPLUS


DOCUMENT NUMBER: 133:68299

TITLE: Direct micro-radioimmunoassay of the new renin
inhibitor CGP 60536

AUTHOR(S): Lefevre, Gilbert; Duval, Martine; Poncin, Alain

CORPORATE SOURCE: Novartis Pharma AG, Clinical Pharmacology, Basel,
Switz.

renin
 AUTHOR(S): Boschke, Richard; Cohen, Nissim Claude; Wood, Jeanette
 M.; Maibaum, Jurgen
 CORPORATE SOURCE: Metabolic Cardiovascular Diseases, Novartis Pharma AG,
 Basel, CH-4002, Switz.
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1997),
 7(21), 2735-2740
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



I

AB Novel low-mol. wt. transition-state peptidomimetic renin inhibitors I (R2 = Me, Et, CHMe2, CH2CHMe2, CMe3, Ph; R3 = H, Ph, CMe3; R4 = H, OH, OBu, OCH2CH:CH2, OCH2CO2Me, OCH2CO2H, OCH2CONH2, OCH2SO2Me; R5 = H, OCH2CO2Et), characterized by an all-carbon 8-Ph substituted octanecarboxamide skeleton have been discovered based on a topog. design approach. The in vitro most potent inhibitors I (R2 = CHMe2, R3 = CMe3, R5 = H; R4 = OCH2CO2Me, OCH2OCONH2, OCH2SO2Me), incorporating a strong H-bond acceptor group linked to the benzyl spacer of the (P3-P1)-unit had IC50 values in the low nanomolar range against human renin.

IT 173399-31-0P 173399-34-3P 173399-50-3P
 198641-46-2P 198641-47-3P 198641-48-4P
 198641-50-8P 198641-51-9P 198641-52-0P
 198641-53-1P 198641-54-2P 198641-55-3P
 198641-57-5P 198641-58-6P 198641-61-1P
 198641-63-3P 198641-65-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(design and prepn. of substituted amino(hydroxy)phenyloctanecarboxamide peptidomimetics as potent human renin inhibitors)

L9 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:995373 HCAPLUS

DOCUMENT NUMBER: 124:201791

TITLE: Preparation of .delta.-amino-.gamma.-hydroxy-.omega.-arylalkanoic acid amides as renin inhibitors.

INVENTOR(S): Goeschke, Richard; Maibaum, Juergen Klaus; Schilling, Walter; Stutz, Stefan; Rigollier, Pascal; Yamaguchi, Yasuchika; Cohen, Nissim Claude; Herold, Peter

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 115 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 678503	A1	19951025	EP 1995-810236	19950407
EP 678503	B1	19990901		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5559111	A	19960924	US 1995-416242	19950404
AT 183997	E	19990915	AT 1995-810236	19950407
ES 2137478	T3	19991216	ES 1995-810236	19950407
FI 9501771	A	19951019	FI 1995-1771	19950412
NO 9501441	A	19951019	NO 1995-1441	19950412
AU 9516421	A1	19951026	AU 1995-16421	19950412
AU 699616	B2	19981210		
ZA 9503051	A	19951018	ZA 1995-3051	19950413
ZA 9503052	A	19951018	ZA 1995-3052	19950413
CA 2147056	AA	19951019	CA 1995-2147056	19950413
ZA 9503050	A	19951108	ZA 1995-3050	19950413
HU 71701	A2	19960129	HU 1995-1078	19950414
HU 74074	A2	19961028	HU 1995-1076	19950414
CZ 287935	B6	20010314	CZ 1995-976	19950414
TW 402582	B	20000821	TW 1995-84103732	19950415
CN 1117960	A	19960306	CN 1995-105037	19950417
IL 113403	A1	20010724	IL 1995-113403	19950417
JP 08081430	A2	19960326	JP 1995-92532	19950418
JP 3240322	B2	20011217		
US 5654445	A	19970805	US 1996-674555	19960702
US 5627182	A	19970506	US 1996-687878	19960725
US 5646143	A	19970708	US 1996-687277	19960725
US 5705658	A	19980106	US 1997-800671	19970214
PRIORITY APPLN. INFO.:			CH 1994-1169	A 19940418
			US 1995-416242	A3 19950404
			US 1996-687277	A3 19960725

OTHER SOURCE(S): MARPAT 124:201791
GI



I

AB Title compds. [I; R1 = H, OH, alkoxy, cycloalkoxy, alkoxyalkoxy, (amidated or esterified) CO2H; R2 = H, alkyl, cycloalkyl, alkoxyalkyl, cycloalkoxyalkyl, OH, hydroxyalkoxy, heteroarylalkyl, etc.; R3 = (halogenated) alkyl, alkoxyalkyl, hydroxyalkyl, (S-oxidized) alkylthioalkyl, etc.; R4 = H, alkyl, OH, alkoxy, cycloalkoxy; R3R4 = alkylendioxy, condensed benzo- or cyclohexeno ring; X = CH2, CHOH; R5 = alkyl, cycloalkyl; R6 = (alkylated alkanoylated) amino; R7 = alkyl, alkenyl, cycloalkyl, aralkyl; R8 = alkyl, cycloalkyl, (esterified or etherified) hydroxyalkyl, (esterified or amidated) carboxyalkyl, etc.], were prepd. Thus, 2(R,S)-methyl-4(S)-hydroxy-5(S)-amino-7(S)-isopropyl-8-(p-tert-butylphenyl)octanoic acid N-butylamide hydrochloride was prepd. in several steps starting with 3-isovaleryl-4(R)-benzyloxazolidin-2-one and p-tert-butylbenzyl bromide. I inhibited human plasma renin with IC50 =

10-6-10-10 M, and reduced blood pressure in marmosets at 0.003-0.3 mg/kg i.v.

IT 172900-85-5P 172900-93-5P 172900-96-8P
 173007-35-7P 173154-08-0P 173154-15-9P
 173333-96-5P 173333-97-6P 173333-98-7P
 173333-99-8P 173334-00-4P 173334-01-5P
 173334-02-6P 173334-03-7P 173334-04-8P
 173334-05-9P 173334-06-0P 173334-07-1P
 173334-08-2P 173334-09-3P 173334-10-6P
 173334-11-7P 173334-12-8P 173334-13-9P
 173334-14-0P 173334-15-1P 173334-16-2P
 173334-17-3P 173334-18-4P 173334-19-5P
 173334-20-8P 173334-21-9P 173334-22-0P
 173334-23-1P 173334-24-2P 173334-25-3P
 173334-26-4P 173334-27-5P 173334-28-6P
 173334-29-7P 173334-30-0P 173334-31-1P
 173334-32-2P 173334-33-3P 173334-34-4P
 173334-35-5P 173334-36-6P 173334-37-7P
 173334-38-8P 173334-39-9P 173334-40-2P
 173334-41-3P 173334-42-4P 173334-43-5P
 173334-44-6P 173334-45-7P 173334-46-8P
 173334-47-9P 173334-48-0P 173334-49-1P
 173334-50-4P 173334-51-5P 173334-52-6P
 173334-53-7P 173334-54-8P 173334-55-9P
 173334-56-0P 173334-57-1P 173334-58-2P
 173334-59-3P 173334-60-6P 173334-61-7P
 173334-62-8P 173334-63-9P 173334-64-0P
 173334-65-1P 173334-66-2P 173334-67-3P
 173334-68-4P 173334-69-5P 173334-70-8P
 173334-71-9P 173334-72-0P 173334-73-1P
 173334-74-2P 173334-75-3P 173334-76-4P
 173334-77-5P 173334-78-6P 173334-79-7P
 173334-80-0P 173334-81-1P 173334-82-2P
 173334-83-3P 173334-84-4P 173334-85-5P
 173334-86-6P 173334-87-7P 173334-88-8P
 173334-89-9P 173334-91-3P 173334-92-4P
 173334-93-5P 173334-94-6P 173334-95-7P
 173334-96-8P 173334-97-9P 173334-98-0P
 173334-99-1P 173335-00-7P 173335-01-8P
 173335-02-9P 173335-03-0P 173335-04-1P
 173335-05-2P 173335-06-3P 173335-07-4P
 173335-08-5P 173335-09-6P 173335-10-9P
 173335-11-0P 173335-12-1P 173335-13-2P
 173335-14-3P 173335-15-4P 173335-16-5P
 173335-17-6P 173335-18-7P 173335-19-8P
 173335-20-1P 173335-21-2P 173335-22-3P
 173335-23-4P 173335-24-5P 173335-25-6P
 173335-26-7P 173335-27-8P 173335-28-9P
 173335-29-0P 173335-30-3P 173335-31-4P
 173335-32-5P 173335-33-6P 173335-34-7P
 173335-35-8P 173335-36-9P 173335-37-0P
 173335-38-1P 173335-39-2P 173335-40-5P
 173335-41-6P 173335-42-7P 173335-43-8P
 173335-44-9P 173335-45-0P 173335-46-1P
 173335-47-2P 173335-48-3P 173335-51-8P
 173335-52-9P 173335-53-0P 173335-54-1P
 173335-55-2P 173335-56-3P 173335-57-4P
 173335-58-5P 173335-59-6P 173335-60-9P
 173335-61-0P 173335-62-1P 173335-63-2P
 173335-64-3P 173335-65-4P 173335-66-5P
 173335-67-6P 173335-68-7P 173335-69-8P
 173335-70-1P 173335-71-2P 173335-72-3P
 173335-73-4P 173335-74-5P 173335-75-6P

173335-76-7P 173335-77-8P 173335-78-9P
 173335-79-0P 173335-80-3P 173335-81-4P
 173335-82-5P 173335-83-6P 173335-84-7P
 173335-85-8P 173335-86-9P 173335-87-0P
 173335-88-1P 173335-92-7P 173398-83-9P
 173398-84-0P 173398-85-1P 173398-86-2P
 173398-87-3P 173398-88-4P 173398-89-5P
 173398-90-8P 173398-91-9P 173398-92-0P
 173398-93-1P 173398-94-2P 173398-95-3P
 173398-96-4P 173398-97-5P 173398-98-6P
 173398-99-7P 173399-00-3P 173399-01-4P
 173399-02-5P 173399-03-6P 173399-04-7P
 173399-05-8P 173399-06-9P 173399-07-0P
 173399-08-1P 173399-09-2P 173399-10-5P
 173399-11-6P 173399-12-7P 173399-13-8P
 173399-14-9P 173399-15-0P 173399-16-1P
 173399-17-2P 173399-18-3P 173399-19-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of .delta.-amino-.gamma.-hydroxy-.omega.-arylalkanoic acid amides as renin inhibitors)

IT 173399-20-7P 173399-24-1P 173399-25-2P
 173399-26-3P 173399-27-4P 173399-28-5P
 173399-29-6P 173399-30-9P 173399-31-0P
 173399-32-1P 173399-33-2P 173399-34-3P
 173399-35-4P 173399-36-5P 173399-37-6P
 173399-38-7P 173399-39-8P 173399-40-1P
 173399-41-2P 173399-43-4P 173399-44-5P
 173399-45-6P 173399-46-7P 173399-47-8P
 173399-48-9P 173399-49-0P 173399-50-3P
 173399-51-4P 173399-52-5P 173399-53-6P
 173399-54-7P 173399-55-8P 173399-56-9P
 173399-57-0P 173399-58-1P 173399-59-2P
 173399-60-5P 173399-61-6P 173399-62-7P
 173399-63-8P 173399-64-9P 173399-65-0P
 173399-66-1P 173399-67-2P 173399-68-3P
 173399-69-4P 173399-70-7P 173399-71-8P
 173399-72-9P 173399-73-0P 173399-74-1P
 173399-75-2P 173399-76-3P 173399-77-4P
 173399-78-5P 173399-79-6P 173399-80-9P
 173399-81-0P 173399-82-1P 173399-83-2P
 173399-84-3P 173399-85-4P 173399-86-5P
 173399-87-6P 173399-88-7P 173399-89-8P
 173399-90-1P 173399-91-2P 173399-92-3P
 173399-93-4P 173399-94-5P 173399-95-6P
 173399-96-7P 173399-97-8P 173399-98-9P
 173399-99-0P 173400-00-5P 173400-01-6P
 173400-02-7P 173400-03-8P 173400-04-9P
 173400-05-0P 173400-06-1P 173400-07-2P
 173400-08-3P 173400-09-4P 173400-10-7P
 173400-11-8P 173400-12-9P 173400-13-0P
 173400-14-1P 173400-15-2P 173400-16-3P
 173400-17-4P 173400-18-5P 173400-19-6P
 173400-20-9P 173400-21-0P 173400-22-1P
 173400-23-2P 173400-24-3P 173400-25-4P
 173400-26-5P 173400-27-6P 173400-28-7P
 173400-29-8P 173400-30-1P 173400-31-2P
 173400-32-3P 173400-33-4P 173400-34-5P
 173400-35-6P 173400-36-7P 173400-37-8P
 173400-38-9P 173400-39-0P 173521-11-4P
 173521-12-5P 173521-13-6P 173521-14-7P
 173521-15-8P 173521-16-9P 173521-17-0P

173521-18-1P 173521-19-2P 173521-20-5P
 173521-21-6P 173521-22-7P 173521-23-8P
 173521-24-9P 173521-25-0P 173521-26-1P
 173521-27-2P 173521-28-3P 173521-29-4P
 173521-30-7P 173521-31-8P 173521-32-9P
 173521-33-0P 173521-34-1P 173521-35-2P
 173521-36-3P 173521-37-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of .delta.-amino-.gamma.-hydroxy-.omega.-arylalkanoic acid amides as renin inhibitors)

L9 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:995369 HCAPLUS

DOCUMENT NUMBER: 124:145882

TITLE: Preparation of chiral 4-(oxotetrahydrofuryl)butyrates and analogs as antihypertensive intermediates

INVENTOR(S): Goeschke, Richard; Herold, Peter; Rigollier, Pascal; Maibaum, Juergen Klaus

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 30 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 678514	A1	19951025	EP 1995-810237	19950407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5606078	A	19970225	US 1995-416237	19950404
FI 9501772	A	19951019	FI 1995-1772	19950412
NO 9501442	A	19951019	NO 1995-1442	19950412
AU 9516420	A1	19951026	AU 1995-16420	19950412
CA 2147052	AA	19951019	CA 1995-2147052	19950413
HU 72110	A2	19960328	HU 1995-1077	19950414
JP 08053434	A2	19960227	JP 1995-92526	19950418
US 5654445	A	19970805	US 1996-674555	19960702
US 5627182	A	19970506	US 1996-687878	19960725
US 5646143	A	19970708	US 1996-687277	19960725
US 5705658	A	19980106	US 1997-800671	19970214
PRIORITY APPLN. INFO.:		CH 1994-1169	A	19940418
		CH 1995-246	A	19950130
		US 1995-416242	A3	19950404
		US 1996-687277	A3	19960725

OTHER SOURCE(S): MARPAT 124:145882
 GI



AB Title compds. [I; R1 = (esterified) CO₂H, CH₂OH, CHO; R₂, R₄ = (cyclo)aliph. group, (hetero)arylaliph. group, etc.; R₃ = N₃, (aryl)aliph. group-substituted NH₂, protected NH₂] were prepd. as intermediates for antihypertensive amides. Thus, 1,4-dibromo-2-butene was dialkylated by 4(S)-benzyl-3-isovealeryloxazolidin-2-one and the brominated product treated with Bu₄NN₃ to give 3-[2(S)-[2(S)-azido-2(S)-[4(S)-isopropyl-5-oxotetrahydrofuran-2(S)-yl]ethyl]-3-methylbutyryl]-4(S)-benzyloxazolidin-2-one which was treated with H₂O₂/LiOH to give 2(S)-[2(S)-azido-2(S)-[4(S)-isopropyl-5-oxotetrahydrofuran-2(S)-yl]ethyl]-3-methylbutyric acid.

IT 173154-08-0P 173154-15-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of chiral 4-(oxotetrahydrofuryl)butyrates and analogs as antihypertensive intermediates)

L9 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:995203 HCAPLUS

DOCUMENT NUMBER: 124:117982

TITLE: Preparation of .alpha.-amino alkanolic acids and reduction products as intermediates in the preparation of renin inhibitors.

INVENTOR(S): Goeschke, Richard

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 45 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 678500	A1	19951025	EP 1995-810238	19950407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5659065	A	19970819	US 1995-416240	19950404
FI 9501773	A	19951019	FI 1995-1773	19950412
NO 9501443	A	19951019	NO 1995-1443	19950412
AU 9516423	A1	19951026	AU 1995-16423	19950412
CA 2147044	AA	19951019	CA 1995-2147044	19950413
JP 08027079	A2	19960130	JP 1995-92827	19950418
US 5654445	A	19970805	US 1996-674555	19960702
US 5627182	A	19970506	US 1996-687878	19960725
US 5646143	A	19970708	US 1996-687277	19960725
US 5705658	A	19980106	US 1997-800671	19970214
PRIORITY APPLN. INFO.:		CH 1994-1169	A	19940418
		CH 1995-247	A	19950130
		US 1995-416242	A3	19950404
		US 1996-687277	A3	19960725

OTHER SOURCE(S): MARPAT 124:117982
GI



I

AB Title compds. [I; R1 = aliphatic, cycloaliphatic, aryl, heteroaryl,

protected or etherified OH, etherified SH, etc.; R2 = aliphatyl, cycloaliphatyl, araliphatyl, heteroaraliphatyl, etc.; R1R2 = divalent aliphatyl; R3 = (esterified) carboxy, formyl; hydroxymethyl; R4 = H, aliphatyl, araliphatyl, protecting group; R5 = H, aliphatyl], were prepd. Thus, glycine anhydride was stirred 64 h with Et3OBF4 in CH2Cl2 to give 76% 3,6-diethoxy-2,5-dihydropyrazine. The latter in THF at -40.degree. was treated with BuLi and then with 2(R)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methylbutyl bromide; the mixt. was stirred 18 h at -20.degree. to give 2(S)-[2(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methylbutyl]-3,6-diethoxy-2,5-dihydropyran. This was stirred 30 min. with HCl in MeCN to give Et 2(S)-amino-4(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-5-methylhexanoate.

IT 172900-85-5P 172900-93-5P 172900-96-8P
173007-35-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of .alpha.-amino alkanolic acids and redn. products as intermediates in the prepn. of renin inhibitors)

L9 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:655365 HCAPLUS

DOCUMENT NUMBER: 121:255365

TITLE: Design and synthesis of a prototypical non-peptidic inhibitor model for the enzyme renin

AUTHOR(S): Hanessian, Stephen; Raghavan, Sadagopan

CORPORATE SOURCE: Dep. Chem., Univ. Montreal, Montreal, H3C 3J7, Can.

SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(14), 1697-702


CODEN: BMCLE8; ISSN: 0960-894X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 121:255365

GI



AB The synthesis of non-peptide acyclic and conformationally constrained compds. is described with the intention of designing models and chem. intermediates, for an inhibitor of the enzyme renin. Thus, amide I was prepd. via stereoselective conjugate addn. of Me2CuLi to butenoate II and condensation of BuNHAlMe2 with furanone III.

IT 158609-92-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. and renin inhibition by).

=>
=>

=> fil caold

FILE 'CAOLD' ENTERED AT 16:31:42 ON 17 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>
=>

=> s 17

L10 0 L7

=>
=>

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:31:51 ON 17 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 APR 2003 HIGHEST RN 503266-82-8
DICTIONARY FILE UPDATES: 16 APR 2003 HIGHEST RN 503266-82-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
=>

=> d reg 17 tot

1	RN	325154-33-4	REGISTRY
2	RN	325154-32-3	REGISTRY
3	RN	198641-65-5	REGISTRY
4	RN	198641-63-3	REGISTRY
5	RN	198641-61-1	REGISTRY
6	RN	198641-58-6	REGISTRY
7	RN	198641-57-5	REGISTRY
8	RN	198641-55-3	REGISTRY
9	RN	198641-54-2	REGISTRY
10	RN	198641-53-1	REGISTRY
11	RN	198641-52-0	REGISTRY
12	RN	198641-51-9	REGISTRY
13	RN	198641-50-8	REGISTRY
14	RN	198641-48-4	REGISTRY
15	RN	198641-47-3	REGISTRY
16	RN	198641-46-2	REGISTRY
17	RN	173521-37-4	REGISTRY
18	RN	173521-36-3	REGISTRY
19	RN	173521-35-2	REGISTRY
20	RN	173521-34-1	REGISTRY
21	RN	173521-33-0	REGISTRY
22	RN	173521-32-9	REGISTRY
23	RN	173521-31-8	REGISTRY
24	RN	173521-30-7	REGISTRY
25	RN	173521-29-4	REGISTRY
26	RN	173521-28-3	REGISTRY
27	RN	173521-27-2	REGISTRY
28	RN	173521-26-1	REGISTRY
29	RN	173521-25-0	REGISTRY
30	RN	173521-24-9	REGISTRY
31	RN	173521-23-8	REGISTRY
32	RN	173521-22-7	REGISTRY
33	RN	173521-21-6	REGISTRY
34	RN	173521-20-5	REGISTRY
35	RN	173521-19-2	REGISTRY
36	RN	173521-18-1	REGISTRY
37	RN	173521-17-0	REGISTRY
38	RN	173521-16-9	REGISTRY
39	RN	173521-15-8	REGISTRY
40	RN	173521-14-7	REGISTRY
41	RN	173521-13-6	REGISTRY
42	RN	173521-12-5	REGISTRY
43	RN	173521-11-4	REGISTRY
44	RN	173400-39-0	REGISTRY
45	RN	173400-38-9	REGISTRY
46	RN	173400-37-8	REGISTRY
47	RN	173400-36-7	REGISTRY
48	RN	173400-35-6	REGISTRY
49	RN	173400-34-5	REGISTRY
50	RN	173400-33-4	REGISTRY
51	RN	173400-32-3	REGISTRY
52	RN	173400-31-2	REGISTRY
53	RN	173400-30-1	REGISTRY
54	RN	173400-29-8	REGISTRY
55	RN	173400-28-7	REGISTRY
56	RN	173400-27-6	REGISTRY
57	RN	173400-26-5	REGISTRY
58	RN	173400-25-4	REGISTRY
59	RN	173400-24-3	REGISTRY
60	RN	173400-23-2	REGISTRY
61	RN	173400-22-1	REGISTRY
62	RN	173400-21-0	REGISTRY
63	RN	173400-20-9	REGISTRY

64	RN	173400-19-6	REGISTRY
65	RN	173400-18-5	REGISTRY
66	RN	173400-17-4	REGISTRY
67	RN	173400-16-3	REGISTRY
68	RN	173400-15-2	REGISTRY
69	RN	173400-14-1	REGISTRY
70	RN	173400-13-0	REGISTRY
71	RN	173400-12-9	REGISTRY
72	RN	173400-11-8	REGISTRY
73	RN	173400-10-7	REGISTRY
74	RN	173400-09-4	REGISTRY
75	RN	173400-08-3	REGISTRY
76	RN	173400-07-2	REGISTRY
77	RN	173400-06-1	REGISTRY
78	RN	173400-05-0	REGISTRY
79	RN	173400-04-9	REGISTRY
80	RN	173400-03-8	REGISTRY
81	RN	173400-02-7	REGISTRY
82	RN	173400-01-6	REGISTRY
83	RN	173400-00-5	REGISTRY
84	RN	173399-99-0	REGISTRY
85	RN	173399-98-9	REGISTRY
86	RN	173399-97-8	REGISTRY
87	RN	173399-96-7	REGISTRY
88	RN	173399-95-6	REGISTRY
89	RN	173399-94-5	REGISTRY
90	RN	173399-93-4	REGISTRY
91	RN	173399-92-3	REGISTRY
92	RN	173399-91-2	REGISTRY
93	RN	173399-90-1	REGISTRY
94	RN	173399-89-8	REGISTRY
95	RN	173399-88-7	REGISTRY
96	RN	173399-87-6	REGISTRY
97	RN	173399-86-5	REGISTRY
98	RN	173399-85-4	REGISTRY
99	RN	173399-84-3	REGISTRY
100	RN	173399-83-2	REGISTRY
101	RN	173399-82-1	REGISTRY
102	RN	173399-81-0	REGISTRY
103	RN	173399-80-9	REGISTRY
104	RN	173399-79-6	REGISTRY
105	RN	173399-78-5	REGISTRY
106	RN	173399-77-4	REGISTRY
107	RN	173399-76-3	REGISTRY
108	RN	173399-75-2	REGISTRY
109	RN	173399-74-1	REGISTRY
110	RN	173399-73-0	REGISTRY
111	RN	173399-72-9	REGISTRY
112	RN	173399-71-8	REGISTRY
113	RN	173399-70-7	REGISTRY
114	RN	173399-69-4	REGISTRY
115	RN	173399-68-3	REGISTRY
116	RN	173399-67-2	REGISTRY
117	RN	173399-66-1	REGISTRY
118	RN	173399-65-0	REGISTRY
119	RN	173399-64-9	REGISTRY
120	RN	173399-63-8	REGISTRY
121	RN	173399-62-7	REGISTRY
122	RN	173399-61-6	REGISTRY
123	RN	173399-60-5	REGISTRY
124	RN	173399-59-2	REGISTRY
125	RN	173399-58-1	REGISTRY
126	RN	173399-57-0	REGISTRY

127	RN	173399-56-9	REGISTRY
128	RN	173399-55-8	REGISTRY
129	RN	173399-54-7	REGISTRY
130	RN	173399-53-6	REGISTRY
131	RN	173399-52-5	REGISTRY
132	RN	173399-51-4	REGISTRY
133	RN	173399-50-3	REGISTRY
134	RN	173399-49-0	REGISTRY
135	RN	173399-48-9	REGISTRY
136	RN	173399-47-8	REGISTRY
137	RN	173399-46-7	REGISTRY
138	RN	173399-45-6	REGISTRY
139	RN	173399-44-5	REGISTRY
140	RN	173399-43-4	REGISTRY
141	RN	173399-41-2	REGISTRY
142	RN	173399-40-1	REGISTRY
143	RN	173399-39-8	REGISTRY
144	RN	173399-38-7	REGISTRY
145	RN	173399-37-6	REGISTRY
146	RN	173399-36-5	REGISTRY
147	RN	173399-35-4	REGISTRY
148	RN	173399-34-3	REGISTRY
149	RN	173399-33-2	REGISTRY
150	RN	173399-32-1	REGISTRY
151	RN	173399-31-0	REGISTRY
152	RN	173399-30-9	REGISTRY
153	RN	173399-29-6	REGISTRY
154	RN	173399-28-5	REGISTRY
155	RN	173399-27-4	REGISTRY
156	RN	173399-26-3	REGISTRY
157	RN	173399-25-2	REGISTRY
158	RN	173399-24-1	REGISTRY
159	RN	173399-20-7	REGISTRY
160	RN	173399-19-4	REGISTRY
161	RN	173399-18-3	REGISTRY
162	RN	173399-17-2	REGISTRY
163	RN	173399-16-1	REGISTRY
164	RN	173399-15-0	REGISTRY
165	RN	173399-14-9	REGISTRY
166	RN	173399-13-8	REGISTRY
167	RN	173399-12-7	REGISTRY
168	RN	173399-11-6	REGISTRY
169	RN	173399-10-5	REGISTRY
170	RN	173399-09-2	REGISTRY
171	RN	173399-08-1	REGISTRY
172	RN	173399-07-0	REGISTRY
173	RN	173399-06-9	REGISTRY
174	RN	173399-05-8	REGISTRY
175	RN	173399-04-7	REGISTRY
176	RN	173399-03-6	REGISTRY
177	RN	173399-02-5	REGISTRY
178	RN	173399-01-4	REGISTRY
179	RN	173399-00-3	REGISTRY
180	RN	173398-99-7	REGISTRY
181	RN	173398-98-6	REGISTRY
182	RN	173398-97-5	REGISTRY
183	RN	173398-96-4	REGISTRY
184	RN	173398-95-3	REGISTRY
185	RN	173398-94-2	REGISTRY
186	RN	173398-93-1	REGISTRY
187	RN	173398-92-0	REGISTRY
188	RN	173398-91-9	REGISTRY
189	RN	173398-90-8	REGISTRY

190	RN	173398-89-5	REGISTRY
191	RN	173398-88-4	REGISTRY
192	RN	173398-87-3	REGISTRY
193	RN	173398-86-2	REGISTRY
194	RN	173398-85-1	REGISTRY
195	RN	173398-84-0	REGISTRY
196	RN	173398-83-9	REGISTRY
197	RN	173335-92-7	REGISTRY
198	RN	173335-88-1	REGISTRY
199	RN	173335-87-0	REGISTRY
200	RN	173335-86-9	REGISTRY
201	RN	173335-85-8	REGISTRY
202	RN	173335-84-7	REGISTRY
203	RN	173335-83-6	REGISTRY
204	RN	173335-82-5	REGISTRY
205	RN	173335-81-4	REGISTRY
206	RN	173335-80-3	REGISTRY
207	RN	173335-79-0	REGISTRY
208	RN	173335-78-9	REGISTRY
209	RN	173335-77-8	REGISTRY
210	RN	173335-76-7	REGISTRY
211	RN	173335-75-6	REGISTRY
212	RN	173335-74-5	REGISTRY
213	RN	173335-73-4	REGISTRY
214	RN	173335-72-3	REGISTRY
215	RN	173335-71-2	REGISTRY
216	RN	173335-70-1	REGISTRY
217	RN	173335-69-8	REGISTRY
218	RN	173335-68-7	REGISTRY
219	RN	173335-67-6	REGISTRY
220	RN	173335-66-5	REGISTRY
221	RN	173335-65-4	REGISTRY
222	RN	173335-64-3	REGISTRY
223	RN	173335-63-2	REGISTRY
224	RN	173335-62-1	REGISTRY
225	RN	173335-61-0	REGISTRY
226	RN	173335-60-9	REGISTRY
227	RN	173335-59-6	REGISTRY
228	RN	173335-58-5	REGISTRY
229	RN	173335-57-4	REGISTRY
230	RN	173335-56-3	REGISTRY
231	RN	173335-55-2	REGISTRY
232	RN	173335-54-1	REGISTRY
233	RN	173335-53-0	REGISTRY
234	RN	173335-52-9	REGISTRY
235	RN	173335-51-8	REGISTRY
DR	173399-42-3		
236	RN	173335-48-3	REGISTRY
237	RN	173335-47-2	REGISTRY
238	RN	173335-46-1	REGISTRY
239	RN	173335-45-0	REGISTRY
240	RN	173335-44-9	REGISTRY
241	RN	173335-43-8	REGISTRY
242	RN	173335-42-7	REGISTRY
243	RN	173335-41-6	REGISTRY
244	RN	173335-40-5	REGISTRY
245	RN	173335-39-2	REGISTRY
246	RN	173335-38-1	REGISTRY
247	RN	173335-37-0	REGISTRY
248	RN	173335-36-9	REGISTRY
249	RN	173335-35-8	REGISTRY
250	RN	173335-34-7	REGISTRY
251	RN	173335-33-6	REGISTRY

252	RN	173335-32-5	REGISTRY
253	RN	173335-31-4	REGISTRY
254	RN	173335-30-3	REGISTRY
255	RN	173335-29-0	REGISTRY
256	RN	173335-28-9	REGISTRY
257	RN	173335-27-8	REGISTRY
258	RN	173335-26-7	REGISTRY
259	RN	173335-25-6	REGISTRY
260	RN	173335-24-5	REGISTRY
261	RN	173335-23-4	REGISTRY
262	RN	173335-22-3	REGISTRY
263	RN	173335-21-2	REGISTRY
264	RN	173335-20-1	REGISTRY
265	RN	173335-19-8	REGISTRY
266	RN	173335-18-7	REGISTRY
267	RN	173335-17-6	REGISTRY
268	RN	173335-16-5	REGISTRY
269	RN	173335-15-4	REGISTRY
270	RN	173335-14-3	REGISTRY
271	RN	173335-13-2	REGISTRY
272	RN	173335-12-1	REGISTRY
273	RN	173335-11-0	REGISTRY
274	RN	173335-10-9	REGISTRY
275	RN	173335-09-6	REGISTRY
276	RN	173335-08-5	REGISTRY
277	RN	173335-07-4	REGISTRY
278	RN	173335-06-3	REGISTRY
279	RN	173335-05-2	REGISTRY
280	RN	173335-04-1	REGISTRY
281	RN	173335-03-0	REGISTRY
282	RN	173335-02-9	REGISTRY
283	RN	173335-01-8	REGISTRY
284	RN	173335-00-7	REGISTRY
285	RN	173334-99-1	REGISTRY
286	RN	173334-98-0	REGISTRY
287	RN	173334-97-9	REGISTRY
288	RN	173334-96-8	REGISTRY
289	RN	173334-95-7	REGISTRY
290	RN	173334-94-6	REGISTRY
291	RN	173334-93-5	REGISTRY
292	RN	173334-92-4	REGISTRY
293	RN	173334-91-3	REGISTRY
294	RN	173334-89-9	REGISTRY
295	RN	173334-88-8	REGISTRY
296	RN	173334-87-7	REGISTRY
297	RN	173334-86-6	REGISTRY
298	RN	173334-85-5	REGISTRY
299	RN	173334-84-4	REGISTRY
300	RN	173334-83-3	REGISTRY
301	RN	173334-82-2	REGISTRY
302	RN	173334-81-1	REGISTRY
303	RN	173334-80-0	REGISTRY
304	RN	173334-79-7	REGISTRY
305	RN	173334-78-6	REGISTRY
306	RN	173334-77-5	REGISTRY
307	RN	173334-76-4	REGISTRY
308	RN	173334-75-3	REGISTRY
309	RN	173334-74-2	REGISTRY
310	RN	173334-73-1	REGISTRY
311	RN	173334-72-0	REGISTRY
312	RN	173334-71-9	REGISTRY
313	RN	173334-70-8	REGISTRY
314	RN	173334-69-5	REGISTRY

315	RN	173334-68-4	REGISTRY
316	RN	173334-67-3	REGISTRY
317	RN	173334-66-2	REGISTRY
318	RN	173334-65-1	REGISTRY
319	RN	173334-64-0	REGISTRY
320	RN	173334-63-9	REGISTRY
321	RN	173334-62-8	REGISTRY
322	RN	173334-61-7	REGISTRY
323	RN	173334-60-6	REGISTRY
324	RN	173334-59-3	REGISTRY
325	RN	173334-58-2	REGISTRY
326	RN	173334-57-1	REGISTRY
327	RN	173334-56-0	REGISTRY
328	RN	173334-55-9	REGISTRY
329	RN	173334-54-8	REGISTRY
330	RN	173334-53-7	REGISTRY
331	RN	173334-52-6	REGISTRY
332	RN	173334-51-5	REGISTRY
333	RN	173334-50-4	REGISTRY
334	RN	173334-49-1	REGISTRY
335	RN	173334-48-0	REGISTRY
336	RN	173334-47-9	REGISTRY
337	RN	173334-46-8	REGISTRY
338	RN	173334-45-7	REGISTRY
339	RN	173334-44-6	REGISTRY
340	RN	173334-43-5	REGISTRY
341	RN	173334-42-4	REGISTRY
342	RN	173334-41-3	REGISTRY
343	RN	173334-40-2	REGISTRY
344	RN	173334-39-9	REGISTRY
345	RN	173334-38-8	REGISTRY
346	RN	173334-37-7	REGISTRY
347	RN	173334-36-6	REGISTRY
348	RN	173334-35-5	REGISTRY
349	RN	173334-34-4	REGISTRY
350	RN	173334-33-3	REGISTRY
351	RN	173334-32-2	REGISTRY
352	RN	173334-31-1	REGISTRY
353	RN	173334-30-0	REGISTRY
354	RN	173334-29-7	REGISTRY
355	RN	173334-28-6	REGISTRY
356	RN	173334-27-5	REGISTRY
357	RN	173334-26-4	REGISTRY
358	RN	173334-25-3	REGISTRY
359	RN	173334-24-2	REGISTRY
360	RN	173334-23-1	REGISTRY
361	RN	173334-22-0	REGISTRY
362	RN	173334-21-9	REGISTRY
363	RN	173334-20-8	REGISTRY
364	RN	173334-19-5	REGISTRY
365	RN	173334-18-4	REGISTRY
366	RN	173334-17-3	REGISTRY
367	RN	173334-16-2	REGISTRY
368	RN	173334-15-1	REGISTRY
369	RN	173334-14-0	REGISTRY
370	RN	173334-13-9	REGISTRY
371	RN	173334-12-8	REGISTRY
372	RN	173334-11-7	REGISTRY
373	RN	173334-10-6	REGISTRY
374	RN	173334-09-3	REGISTRY
375	RN	173334-08-2	REGISTRY
376	RN	173334-07-1	REGISTRY
377	RN	173334-06-0	REGISTRY

378	RN	173334-05-9	REGISTRY
379	RN	173334-04-8	REGISTRY
380	RN	173334-03-7	REGISTRY
381	RN	173334-02-6	REGISTRY
382	RN	173334-01-5	REGISTRY
383	RN	173334-00-4	REGISTRY
384	RN	173333-99-8	REGISTRY
385	RN	173333-98-7	REGISTRY
386	RN	173333-97-6	REGISTRY
387	RN	173333-96-5	REGISTRY
388	RN	173154-15-9	REGISTRY
389	RN	173154-08-0	REGISTRY
390	RN	173007-35-7	REGISTRY
391	RN	172900-96-8	REGISTRY
392	RN	172900-93-5	REGISTRY
393	RN	172900-85-5	REGISTRY
394	RN	158609-92-8	REGISTRY

=>

=>

=> d ide can 17 1 3 10 17 20 25 30 35 40 44 50 55 60 65 70 75 80 84 180 197 285 384 388
 390 391 394

L7 ANSWER 1 OF 394 REGISTRY COPYRIGHT 2003 ACS

RN 325154-33-4 REGISTRY

CN Benzeneoctanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-
 .gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-
 methylethyl)-, (.alpha.S,.gamma.S,.delta.R,.zeta.S)-, (2E)-2-butenedioate
 (1:1) (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C30 H53 N3 O6 . C4 H4 O4

SR CA


LC STN Files: CA, CAPLUS

CM 1

CRN 325154-32-3

CMF C30 H53 N3 O6

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:162829

L7 ANSWER 3 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 198641-65-5 REGISTRY
CN Benzeneoctanamide, .delta.-amino-N-butyl-4-(1,1-dimethylethyl)-.gamma.-hydroxy-.alpha.-methyl-.zeta.-(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, (.gamma.S,.delta.S,.zeta.S)-[partial]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H50 N2 O5 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 127:359067

L7 ANSWER 10 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 198641-53-1 REGISTRY
CN Benzeneoctanamide, .delta.-amino-N-butyl-.zeta.,4-bis(1,1-dimethylethyl)-.gamma.-hydroxy-.alpha.-methyl-, (.gamma.S,.delta.S,.zeta.S)-[partial]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H48 N2 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 127:359067

```
L7 ANSWER 17 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 173521-37-4 REGISTRY
CN Benzeneoctanamide, .delta.-amino-.gamma.-hydroxy-4-methoxy-3-(3-
methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-N-[(5-oxo-2-
pyrrolidinyl)methyl]-, [2R-{2R*(.alpha.S*,.gamma.S*,.delta.S*,.zeta.S*)}]-
(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H51 N3 O6
CI COM
SR CA
LC STN Files: CA, CAPLUS
```

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP'. FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

```
L7 ANSWER 20 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 173521-34-1 REGISTRY
CN Benzeneoctanamide, .delta.-amino-N-[2-(3,5-dimethyl-4-morpholinyl)ethyl]-
.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.-methyl-.zeta.-(1-
methylethyl)-, [4(.alpha.R)-[3.alpha.,4(.alpha.R*,.gamma.S*,.delta.S*,.zet
a.R*),5.alpha.]]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H55 N3 O6
CI COM
SR CA
LC STN Files: CA, CAPLUS
```

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 25 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 173521-29-4 REGISTRY
CN Benzeneoctanamide, .delta.-amino-N-butyl-4-(1,1-dimethylethyl)-3-(3,3-dimethyl-2-oxobutoxy)-.gamma.-hydroxy-.alpha.-methyl-.zeta.-(1-methylethyl)-, [.alpha.S-(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C32 H56 N2 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 30 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 173521-24-9 REGISTRY
CN Benzeneoctanamide, .delta.-amino-N-butyl-4-(1,1-dimethylethyl)-.gamma.-hydroxy-.alpha.-methyl-.zeta.-(1-methylethyl)-3-[(1-oxido-2-pyridinyl)methoxy]-, [.alpha.S-(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H51 N3 O4

CI COM
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 35 OF 394 REGISTRY COPYRIGHT 2003 ACS
 RN 173521-19-2 REGISTRY
 CN 2-Butenoic acid, 4-[5-[4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester, [2S-(2R*,4R*,5R*,7R*)]-(9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H52 N2 O5
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.
 Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 40 OF 394 REGISTRY COPYRIGHT 2003 ACS
 RN 173521-14-7 REGISTRY
 CN Benzeneoctanamide, .delta.-amino-N-(3-amino-2-methyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-,

[.alpha.S-[N(S*),.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H51 N3 O6
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 44 OF 394 REGISTRY. COPYRIGHT 2003 ACS
 RN 173400-39-0 REGISTRY
 CN Benzeneoctanamide, .delta.-amino-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-N-[(2-oxo-4-thiazolidinyl)methyl]-, [4R-[4R*(.alpha.S*,.gamma.S*,.delta.S*,.zeta.S*)]]-(9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H49 N3 O6 S
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 50 OF 394 REGISTRY COPYRIGHT 2003 ACS
 RN 173400-33-4 REGISTRY
 CN Benzeneoctanamide, .delta.-amino-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-N-[(2-oxo-3-pyrrolidinyl)methyl]-, [3R-[3R*(.alpha.S*,.gamma.S*,.delta.S*,.zeta.S*)]]-(9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H51 N3 O6
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 55 OF 394 REGISTRY COPYRIGHT 2003 ACS
 RN 173400-28-7 REGISTRY
 CN Benzeneoctanamide, .delta.-amino-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-N-[2-[(methylamino)sulfonyl]ethyl]-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]]-(9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H51 N3 O7 S
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 60 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 173400-23-2 REGISTRY
CN Benzeneoctanamide, .delta.-amino-N-[1-(aminocarbonyl)butyl]-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H53 N3 O6
CI COM
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 65 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 173400-18-5 REGISTRY
CN Benzeneoctanamide, .delta.-amino-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-N-[2-(4-morpholinylamino)-2-oxoethyl]-, [.alpha.S-(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H54 N4 O7
CI COM
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 70 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 173400-13-0 REGISTRY
CN Propanoic acid, 3-[[5-amino-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-(1-methylethyl)-1-oxononyl]amino]-2,2-dimethyl-, [2S-(2R*,4R*,5R*,7R*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H52 N2 O7
CI COM
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 75 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 173400-08-3 REGISTRY
CN Benzeneoctanamide, .delta.-amino-N-[2-amino-1-(hydroxymethyl)-2-oxoethyl]-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]- (9CI)

(CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H49 N3 O7
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 80 OF 394 REGISTRY COPYRIGHT 2003 ACS
 RN 173400-03-8 REGISTRY
 CN Benzeneoctanamide, .delta.-amino-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.-methyl-.zeta.-(1-methylethyl)-N-[3-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-, [.alpha.R-(.alpha.R*,.gamma.S*,.delta.S*,.zeta.S*)]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H48 N4 O6
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 84 OF 394 REGISTRY COPYRIGHT 2003 ACS
 RN 173399-99-0 REGISTRY
 CN Benzeneoctanamide, .delta.-amino-N-[2-(ethylsulfonyl)ethyl]-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.-methyl-.zeta.-(1-methylethyl)-, [.alpha.R-(.alpha.R*,.gamma.S*,.delta.S*,.zeta.S*)]- (9CI)
 (CA INDEX NAME)
 FS STEREOSEARCH
 MF C27 H48 N2 O7 S
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 180 OF 394 REGISTRY COPYRIGHT 2003 ACS
 RN 173398-99-7 REGISTRY
 CN Benzeneoctanamide, .delta.-amino-3-[(2-aminophenyl)methoxy]-N-butyl-4-(1,1-dimethylethyl)-.gamma.-hydroxy-.alpha.-methyl-.zeta.-(1-methylethyl)-, monohydrochloride, [.alpha.S-(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C33 H53 N3 O3 . Cl H
 SR CA
 LC STN Files: CA, CAPLUS
 CRN (173521-31-8)

Absolute stereochemistry.




● HCl

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 197 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 173335-92-7 REGISTRY
CN Benzeneoctanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-
.gamma.-hydroxy-4-methoxy-3-(4-methoxy-1-butenyl)-.alpha.,.zeta.-bis(1-
methylethyl)-, [.alpha.S-(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C31 H53 N3 O5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 124:201791

L7 ANSWER 285 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 173334-99-1 REGISTRY
CN Benzeneoctanamide, .delta.-amino-.gamma.-hydroxy-4-methoxy-3-(3-
methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-N-[3-(4-

morpholinyl)propyl]-, dihydrochloride, [.alpha.S-
(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]- (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C32 H57 N3 O6 . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS
CRN (173399-12-7)

Absolute stereochemistry.




● 2 HCl

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 384 OF 394 REGISTRY COPYRIGHT 2003 ACS
RN 173333-99-8 REGISTRY
CN Benzeneoctanamide, .delta.-amino-N-butyl-4-(1,1-dimethylethyl)-.gamma.,3-
dihydroxy-.alpha.-methyl-.zeta.-(1-methylethyl)-, monohydrochloride,
[.alpha.R-(.alpha.R*,.gamma.S*,.delta.S*,.zeta.S*)]- (9CI) (CA INDEX
NAME)
FS STEREOSEARCH
MF C26 H46 N2 O3 . Cl H
SR CA
LC STN Files: CA, CAPLUS
CRN (173399-31-0)

Absolute stereochemistry.




● HCl

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

L7 ANSWER 388 OF 394 REGISTRY COPYRIGHT 2003 ACS
 RN 173154-15-9 REGISTRY
 CN Benzeneoctanamide, .delta.-amino-.gamma.-hydroxy-4-(3-hydroxypropoxy)-3-(3-methoxypropoxy)-.alpha.,.zeta:-bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, [.alpha.S-(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C33 H59 N3 O7 . Cl H
 SR CA
 LC STN Files: CA, CAPLUS
 CRN (173399-85-4)

Absolute stereochemistry.




2 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

REFERENCE 2: 124:145882

L7 ANSWER 390 OF 394 REGISTRY COPYRIGHT 2003 ACS
 RN 173007-35-7 REGISTRY
 CN Benzeneoctanamide, .delta.-amino-N-butyl-4-(1,1-dimethylethyl)-.gamma.-hydroxy-.alpha.-methyl-.zeta.-(1-methylethyl)-, monohydrochloride, [.alpha.S-(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H46 N2 O2 . Cl H
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 CRN (173399-26-3)

Absolute stereochemistry.



● HCl

2 REFERENCES IN FILE CA (1962 TO DATE)

2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

REFERENCE 2: 124:117982

L7 ANSWER 391 OF 394 REGISTRY COPYRIGHT 2003 ACS

RN 172900-96-8 REGISTRY

CN Benzeneoctanamide, .delta.-amino-N-butyl-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.-methyl-.zeta.-(1-methylethyl)-, monohydrochloride, [.alpha.R-(.alpha.R*,.gamma.S*,.delta.S*,.zeta.S*)]- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C27 H48 N2 O5 . C1 H

SR CA

LC STN Files: ADISINSIGHT, CA, CAPLUS, SYNTHLINE, USPATFULL

CRN (173399-55-8)

Absolute stereochemistry.



● HCl

2 REFERENCES IN FILE CA (1962 TO DATE)

2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:201791

REFERENCE 2: 124:117982

L7 ANSWER 394 OF 394 REGISTRY COPYRIGHT 2003 ACS

RN 158609-92-8 REGISTRY

CN Benzeneoctanamide, .delta.-amino-N-butyl-.gamma.-hydroxy-.alpha.,.zeta.-dimethyl-, [.alpha.R-(.alpha.R*,.gamma.S*,.delta.S*,.zeta.S*)]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C20 H34 N2 O2

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 121:255365